ICTM logo
AB01
A randomised trial of epirubicin and cyclosphamide versus epirubicin and paclitaxel in the treatment of women with metastatic breast cancer
Can a new combination of drugs help to treat people with breast cancer that has spread?
What was this study about?

In the early 1990s doctors usually treated women with breast cancer that had spread to other parts of their body with two chemotherapy drugs – epirubicin and cyclosphamide. But researchers had found that another chemotherapy drug called paclitaxel might be more effective.

The AB01 trial aimed to test whether a new chemotherapy treatment of epirubicin and paclitaxel would be more effective than the usual treatment at that time – epirubicin and cyclosphamide.

Who was included?

705 patients with breast cancer that had spread to other parts of their body. They came from 62 different hospitals.

What difference did this study make?

This trial found that the new chemotherapy treatment was no more effective than the usual chemotherapy treatment.

NICE used the results of this study to recommend that paclitaxel should not be used to treat women with breast cancer that had spread to other parts of their body.

Contact details

When did it take place?

This trial began recruiting patients in 1996 and closed to recruitment in 1999. The results were published in 2005.

Where did it take place?

Who funded the study?

The Medical Research Council, with contributions from the pharmaceutical companies Bristol Myers-Squibb, Pharmacia and Upjohn.

Further information


Type of study:
Randomised trial
Status:
Closed
Study start date:

Related Publications

Ahmed, H.U., El-Shater Bosaily, A., Brown, L.C., Gabe, R., Kaplan, R., Parmar, M.K., Collaco-Moraes, Y., Ward, K., Hindley, R.G., Freeman, A., Kirkham, A.P., Oldroyd, R., Parker, C., Emberton, M., Promis study gro.

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389:815-822

Cafferty, F.H., Coyle, C., Rowley, S., Berkman, L., MacKensie, M., Langley, R.

Co-enrolment of participants into multiple cancer trials: benefits and challenges. Clinical Oncology. 2017; 29:e126-e133

Gillessen, S., Attard, G., Beer, T.M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B.H., Clarke, N., Daugaard, G., Davis, I.D., de Bono, J., Dos Reis, R B., Drake, C.G., Eeles, R., Efstathiou, E., Evans, C.P., Fanti, S., Feng, F., Fizazi, K., Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Higano, C.S., James, N., Kantoff, P., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Kramer, G., Logothetis, C., Maluf, F., Morgans, A.K., Morris, M.J., Mottet, N., Murthy, V., Oh, W., Ost, P., Padhani, A.R., Parker, C., Pritchard, C.C., Roach, M., Rubin, M.A., Ryan, C., Saad, F., Sartor, O., Scher, H., Sella, A., Shore, N., Smith, M., Soule, H., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Tannock, I., Tombal, B., Valdagni, R., Wiegel, T., Omlin, .

Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. European Association of Urololgy. 2017.

James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Ritchie, A.W.S., Amos, C.L., Gilson, C., Jones, R.J., Matheson, D., Millman, R., Attard, G., Chowdhury, S., Cross, W.R., Gillessen, S., Parker, C.C., Russell, J.M., Berthold, D.R., Brawley, C., Adab, F., Aung, S., Birtle, A.J., Bowen, J., Brock, S., Chakraborti, P., Ferguson, C., Gale, J., Gray, E., Hingorani, M., Hoskin, P.J., Lester, J.F., Malik, Z.I., McKinna, F., McPhail, N., Money-Kyrle, J., O'Sullivan, J., Parikh, O., Protheroe, A., Robinson, A., Srihari, N.N., Thomas, C., Wagstaff, J., Wylie, J., Zarkar, A., Parmar, M.K.B., Sydes, M.R., Stampede Investigato.

Abiraterone for prostate cancer not previously treated with hormone therapy. The New England Journal of Medicine. 2017.

Lemanska, A., Chen, T., Dearnaley, D.P., Jena, R., Sydes, M.R., Faithfull, .

Symptom clusters for revising scale membership in the analysis of prostate cancer patient reported outcome measures: a secondary data analysis of the Medical Research Council RT01 trial (ISCRTN47772397). Quality of Life Research. 2017.